Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment

Cemiplimab is a highly potent, hinge-stabilized human IgG4 monoclonal antibody (mAb) targeting programmed cell death 1 (PD-1) receptor approved for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (SCC) who are not candidates for curative surgery or curative radiation....

Descripción completa

Detalles Bibliográficos
Autores principales: Gambale, Elisabetta, Fancelli, Sara, Caliman, Enrico, Petrella, Maria Cristina, Doni, Laura, Pillozzi, Serena, Antonuzzo, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804682/
https://www.ncbi.nlm.nih.gov/pubmed/35101944
http://dx.doi.org/10.1136/jitc-2021-003540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804682/
https://www.ncbi.nlm.nih.gov/pubmed/35101944
http://dx.doi.org/10.1136/jitc-2021-003540

Ejemplares similares